TC BioPharm (Holdings) plc - ADR

-0.03 (-2.61%)
Products, Regulatory

TC Biopharm Receives MHRA And Research Ethics Committee Approvals To Initiate Phase 2B/3 Clinical Trials For Treatment Of Acute Myeloid Leukemia

Published: 03/23/2022 13:28 GMT
(TCBP) - Tc Biopharm Receives Mhra and Research Ethics Committee Approvals to Initiate Phase 2b/3 Clinical Trials for Treatment of Acute Myeloid Leukemia.
Tc Biopharm - Trial Enrollment Expected to Begin During First Half of 2022.
Tc Biopharm - Phase 2/3 Trials Will Begin Enrollment in First Half of 2022 in Uk With Expansion Into US Following Shortly Thereafter.